Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week

Dna, Genetic Material, Helix, Proteins, BiologyImage Source: UnsplashAn IntroductionThis article highlights the 10 clinical-stage AI-powered (designated with *) and psychedelic compound-based (designated with **)  small cap ($400M to $2.0B) drug discovery companies in the  Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week, in descending order, and MTD and their areas of focus, along with their latest news, analyses and commentary where available.

  •  **GH Research (GHRS): UP 8.7% last week; UP 30.4% MTD

    • focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamineGo here for much more extensive information on DMT.
    • Latest news, commentary and/or analysis:
      • Recent Price Trend in GH Research is Your Friend, Here’s Why
  • *AbCellera Biologics (ABCL): UP 5.8% last week; UP 2.4% MTD

    • develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
    • Latest news, commentary and/or analysis:
      • AbCellera Reports Q1 2024 Business Results
  • *Relay Therapeutics (RLAY): UP 2.7% last week; UP 7.1% MTD

    • specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
    • Latest news, commentary and/or analysis:
      • Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
  • **Mind Medicine (MNMD): UP 0.1% last week; DOWN 3.4% MTD

    • focuses on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
    • Latest news, commentary and/or analysis:
      • MindMed Reports 1stQ 2024 Financial Results
  • *Recursion Pharmaceuticals (RXRX): DOWN 2.8% last week; UP 12.8% MTD

    • has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
    • Latest news, commentary and/or analysis:
      • Here is What to Know Beyond Why Recursion Pharmaceuticals is a Trending Stock
  • *Schrödinger (SDGR): DOWN 3.4% last week; DOWN 8.3% MTD

    • specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
    • Latest news, commentary and/or analysis:
      • Schrödinger Reports First Quarter 2024 Financial Results
  • **Compass Pathways (CMPS): DOWN 4.6% last week; DOWN 5.8% MTD

    • focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
    • Latest news, commentary and/or analysis:
      • These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
  • **atai Life Sciences (ATAI): DOWN 5.8% last week; DOWN 16.6% MTD

    • focuses on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
    • Latest news, commentary and/or analysis:
      • atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
  • *Absci Corporation (ABSI): DOWN 8.9% last week; DOWN 8.1% MTD

    • focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
    • Latest news, commentary and/or analysis: 
      • Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
  • *Exscientia (EXAI): DOWN 9.8% last week; UP 16.4% MTD

    • reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
    • Latest news, commentary and/or analysis:
      • Analysts Are Upgrading Exscientia After Its Latest Results
      • Analysts Are Upgrading Exscientia After Its Latest Results
  • SummaryOn average, the above 10 stocks were DOWN 1.1% last week and are now DOWN 0.6% MTD and DOWN 11.7% YTD.

    Print Friendly, PDF & Email

    Author: Travis Esquivel

    Travis Esquivel is an engineer, passionate soccer player and full-time dad. He enjoys writing about innovation and technology from time to time.

    Share This Post On

    Submit a Comment

    Your email address will not be published. Required fields are marked *